Article

Travoprost 0.004% gets Japan's approval

Japan's Ministry of Health, Labor, and Welfare has approved travoprost ophthalmic solution 0.004% (Travatan Z) for the treatment of glaucoma and ocular hypertension.

Tokyo-Japan's Ministry of Health, Labor, and Welfare has approved travoprost ophthalmic solution 0.004% (Travatan Z) for the treatment of glaucoma and ocular hypertension.

"Travoprost solution provides doctors with a new treatment option that may address an unmet need of many glaucoma patients-a prostaglandin analogue without benzalkonium chloride," Yoshiaki Kitazawa, MD, PhD, and director, Akasaka Kitazawa Eye Clinic, said in a prepared statement.

Japan has the distinction of having the world's second-largest population with glaucoma.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.